Tumor-induced immune suppression is a fundamental problem in cancer biology and immunotherapy. COX metabolites act as tumor promoters when overproduced (1-3), and recent studies have demonstrated that the COX metabolite prostaglandin E 2 (PGE 2 ) exhibits potent immunosuppressive effects, orchestrating an imbalance between type 1 and type 2 cytokines (4-6). PGE 2 mediates its effects, in part, through G proteincoupled PGE receptors, designated EP1, EP2, EP3, and EP4. Differential expression of these EP receptors mediate the diverse, and often antagonistic, effects of PGE 2 and its analogues on a variety of cell types (7-9). The EP2 receptor regulates the activation and differentiation of mouse B lymphocytes (10), modulates T cell development (11-12), and regulates macrophage cytokine release (13) and postsurgery immune responses (14). The EP2 receptor also plays a key role in the differentiation of macrophage-like osteoclast cells as well as the functional response of osteoclasts to PGE 2 (15). Importantly, PGE 2 has been shown to be a key modulator of DC function, altering cytokine production as well as the I-A d class II cell surface marker (16) (17) . Despite data describing the production of PGE 2 by tumors and the expression of the EP2 receptor in specific immune populations, the role of the EP2 receptor in modulation of the host immune response to tumors remains uncharacterized.
receptor in PGE 2 -induced inhibition of DC differentiation and function and as a mediator of cancerassociated immunodeficiency.
Methods
Mice. EP2 -/-mice were generated as described (21) and backcrossed for ten generations onto both the C57BL/6 and the BALB/c background strains. Eightto ten-week-old female mice used in the study were housed in pathogen-free units at Vanderbilt University School of Medicine, in compliance with Institutional Animal Care and Use Committee regulations. EP2-null BALB/c mice were crossed with BALB/c with a transgenic T cell receptor (TCR) specific for the ovalbumin peptide OVA 323-339 (22) .
Reagents. Ab-producing hybridomas were obtained from the American Type Culture Collection (Manassas, Virginia, USA) and used as culture supernatants: anti-CD4 (L3T4, TIB-207), anti-CD8 (Lyt-2.2, TIB-210), and anti-MHC class II (TIB-120). Mouse GM-CSF was obtained from R&D Systems Inc. (Minneapolis, Minnesota, USA). Anti-CD3, anti-CD28, and anti-CD69 were obtained from PharMingen (San Diego, California, USA). FITC-conjugated antiCD11c was purchased from PharMingen. Isotypematched FITC-conjugated IgG was used as a control of nonspecific binding. PGE 2 is from Cayman Chemical (Ann Arbor, Michigan, USA). FITC-conjugated or phycoerythrin-conjugated (PE-conjugated) Ab's were purchased from PharMingen.
Cell culture. The MC26 colorectal cancer cell line, Lewis lung carcinoma cell line, 3LL, and R8, an Abelson leukemia virus-transformed cell line, as well as RMA-S cells, were maintained according to standard cell-culture techniques.
RT-PCR analysis of EP2 receptor expression in bone marrow progenitors. Total RNA was extracted from bone marrow progenitors of BALB/c-EP2 -/-and wild-type mice (EP2 +/+ ) with an RNeasy Mini Kit (QIAGEN Inc., Valencia, California, USA). Primers specific for the EP2 receptor (sense: 5′-CCGGGGTTCTGGGGAATC-3′; antisense: 5′-AACCTCAGGACCGGTGGC-3′) were used in RT-PCR analysis.
Bone marrow-derived DC culture and FACs analysis. Bone marrow was obtained from the femurs and tibias of BALB/c-EP2 -/-and wild-type mice. The cells were then enriched for hematopoietic cells by depletion of lineage-specific cells with a mixture of Ab's (TIB-207, TIB-210, and TIB-120) and complement (Cedarlane Laboratories Ltd., Hornby, Ontario, Canada) and subsequent gradient-density centrifugation on Lympholyte M (Cedarlane Laboratories Ltd.) to remove dead cells. Progenitors were cultured in GM-CSF-containing medium to generate DCs. PGE 2 or vehicle was added to the DC cell cultures every 24 h. DCs were harvested and washed in PBS and labeled with anti-CD11c and other Ab's for 30 minutes at 4°C. To investigate the number of DCs and CD4 + and CD8 + T cells in draining lymph nodes of tumor-bearing mice, single-cell suspensions of inguinal lymph nodes from tumor-bearing EP2 -/-and wild-type mice were prepared 21 days after MC26 inoculation, the time at which we observed the maximum tumor growth difference between EP2 -/-and wild-type control mice. Cells were labeled with PEconjugated anti-H2IA d , anti-CD11c, anti-CD4, or anti-CD8 Ab's, washed, and analyzed on a FACScan flow cytometer (Becton Dickinson Immunocytometry Systems, Mountain View, California, USA).
Measurements of T cell cytokine production. CD4 T cells from lymph nodes of EP2 wild-type or EP2-null animals were enriched by complement-mediated lysis using anti-CD8 anti-MHC class II and then stimulated to differentiate to Th1 or Th2 cells as described (23) . Briefly, cells were incubated with immobilized anti-CD3, anti-CD28 Ab's, and recombinant mouse IL-2, in the presence of neutralizing polyclonal Ab against mouse IL-4 (for Th1) or IL-12 (for Th2), as appropriate. Washed cells (day 6) were restimulated with immobilized anti-CD3 plus anti-CD28 for 24 h before collection of culture supernatants for determination of cytokine production. Cytokine (IL-4 and IFN-γ) levels from culture supernatants were determined by standard ELISA according to the manufacturer's instructions (PharMingen).
Measurements of PGE 2 concentration. Draining lymph nodes, tumor tissues, and serum of tumor-bearing mice were collected, and their purification, derivation, and analysis of PGE 2 by gas chromatography/mass spectrometry were performed as described (24) (25) .
T cell proliferation. For alloreactive mixed lymphocyte reaction (MLR), single-cell suspensions were prepared from inguinal, axillary, and brachial lymph nodes of wild-type C57BL/6 mice. Red cells were removed by hypotonic shock. T cells were enriched using hybridoma supernatant (TIB 120, anti-class II; American Type Culture Collection) and the complement depletion method followed by enrichment by Lympholyte M gradient-density centrifugation for 20 min at 600 g. T cells were collected from the interface, washed, and used in the MLR assay. Day 9 DCs from BALB/c-EP2 -/-and wild-type mice, treated with or without PGE 2 , were irradiated with 20 Gy, plated in triplicate, and incubated with allogeneic T cells for 72 h. Eighteen hours before harvesting, all cultures were pulsed with [ 3 H] thymidine (Amersham Life Sciences Inc., Arlington Heights, Illinois, USA). Incorporation of [ 3 H] thymidine was counted using a liquid scintillation counter and expressed as counts per minute.
For peptide-induced proliferation, day 9 bone marrow-derived DCs (10 5 ) from wild-type BALB/c mice were irradiated and pulsed with varying concentrations of OVA 323-339 peptide for 2 h. T cells (4 × 10 5 ), prepared as described above from the lymph nodes and spleen of DO11. 10 Responder cells were harvested and used at different ratios in a cytotoxic T lymphocyte (CTL) assay using 51 Cr-labeled MC26 as target cells. After 6 h, supernatants were harvested, and the released radioactivity was measured. R8, an H2 b/d cell line, was used as a specificity control. The percentage of the ratio between the difference of specific release and spontaneous release to the difference of maximum and spontaneous release was used to calculate specific lysis.
Isograft models of tumor biology. For the MC26 tumor model, 100 µl of 5 × 10 6 cells/ml MC26 cell suspension in PBS was injected subcutaneously into the right flank of BALB/c-EP2 -/-and wild-type control mice. The size of the tumor was determined by direct measurement of tumor dimensions at 2-to 3-day intervals, using calipers. To quantitate tumor volume the equation, volume = [length × (width) 2 ] × 0.5, was used. For the 3LL tumor model, cell suspension containing 5 × 10 5 cells in 100 µl was injected into tail veins of the wild-type C57BL/6 or EP2 -/-mice. The time of death, or when mice became moribund, was recorded and plotted as percentage of survival. The lungs were taken from each animal immediately after death and weighed.
Immunohistochemistry and mouse VEGF immunoassay. Tumor samples from MC26 mice model were fixed with 4% paraformaldehyde, embedded in paraffin, and sections stained using an anti-CD31 Ab from Research Diagnostics Inc. used at a 1:400 dilution. For the VEGF immunoassay, we followed the protocol described by Marti et al. (26) , quantitated using a commercially available immunoassay kit (Quantikine M; R&D Systems Inc.).
Statistical analysis. Tests of hypotheses concerning the significant difference of the tumor growth between EP2 -/-and wildtype controls across different time points were made using the restricted/residual maximum likelihood-based mixed effect model to adjust the intracorrelation effect for the repeated measurements of the tumor volume (in millimeters cubed) from the same mouse. For lifetime data analyses, the two groups (EP2 -/-vs. wild-type controls) were compared for survival with Kaplan-Meier estimates and log-rank tests. For the single time point data, tests of hypotheses between groups were made using either the ANOVA with adjusted leastsquares means or the χ-square test for the interesting continuous or categorical variables, respectively. All tests of significance were two sided, and differences were considered statistically significant when P values were less than 0.05. All data were expressed as means ± SE. SAS version 8.0 was used for all analyses (SAS Institute Inc., Carey, North Carolina, USA).
Results
Attenuated tumor growth and prolonged survival in EP2 -/-mice. To determine whether the EP2 receptor is important in the escape of tumors from host immune responses, we examined whether tumor growth was suppressed in EP2 -/-mice relative to wild-type control animals. The syngeneic colorectal cancer cell line MC26 was chosen because it exhibits constitutive COX-2 expression. MC26 cells were injected subcutaneously into wild-type or EP2-null BALB/c mice. Colorectal cancer cells grew rapidly as solid tumors in the wildtype host, whereas the tumor growth, including tumor volume and growth rate, were significantly attenuated in EP2 -/-hosts (P < 0.05) (Figure 1a ). Similar results were observed with C57BL/6-derived Lewis lung carcinoma (3LL) in EP2 -/-C57BL/6 animals. The survival of EP2 -/-mice was significantly prolonged compared with wild-type control animals after i.v. injection of 3LL cells ( Figure 1b ). Terminal lung weight from wild-type mice was also significantly higher than that of EP2 -/-(875 mg, wild type; 557 mg, EP2 -/-, P < 0.05).
Tumor angiogenesis was not different between tumors from EP2 -/-and wild-type animals. It has been observed that tumor vascularity was decreased in tumors transplanted into COX-2-deficient mice (2), and EP2-mediated signals have been implicated in tumor angiogenesis 19) . To determine whether the reduced tumor growth rate in the EP2 -/-background could be explained by effects in tumor angiogenesis, we stained tumor samples from EP2 -/-and wild-type mice with anti-CD31 Ab, a marker for endothelial cells. Blood vessels were counted in more than ten high-power fields from four independent MC26 tumors from each background in a blinded evaluation by two independent pathologists. No difference in blood vessel number was observed, with an average of 6.56 ± 0.76 and 7.31 ± 1.5 vessels per ×400 field (P = 0.498) observed in tumors from EP2 -/-and wild-type mice, respectively (Figure 2a) . Similarly, no difference in CD31 staining was observed in solid tumors in the 3LL model (data not shown). In addition, we observed no difference in VEGF levels in tumor lysates from EP2 -/-and wild-type mice (Figure 2b , P = 0.975). These data suggest that alterations in angiogenesis or angiogenic drive do not explain the observed differences in tumor growth between wild-type and EP2 -/-mice.
T cell-intrinsic function in EP2-null mice. We hypothesized that the differences in tumor growth rates could be explained by EP2 receptor-mediated immune suppression of the host antitumor response. PGE 2 might directly affect T cell function through the EP2 receptor. To test whether disruption of the EP2 receptor caused a change in T cell-elaborated cytokine production, T cells were isolated from wildtype or EP2-null mice, differentiated into Th1 or Th2 type, and cytokine production was measured after restimulation. The Th1/Th2 cytokine ratio was indistinguishable for both genetic backgrounds (Table 1) . We next tested whether the ability of EP2-null T cells to respond to a specific peptide antigen was altered. BALB/c EP2-null mice were crossed with DO11.10 mice, which bear an ovalbumin-specific TCR transgene (22) . T cells isolated from DO11.10 mice that were EP2 +/+ , EP2 +/-, or EP2 -/-receptor null were stimulated with the wild-type DCs pulsed with the ovalbumin peptide antigen. Ovalbumin peptide-pulsed (OVA 323-339) DCs stimulated EP2 +/+ , EP2 +/-, and EP2 -/-T cells in a dose-dependent manner. There was no enhancement of the proliferation of EP2-null T cells, and, in fact, loss of the EP2 receptor decreased the ability of ovalbumin-specific T cells to respond to antigen ( Figure 3 ). Taken together, these data indicate that the absence of the EP2 receptor does not appear to enhance intrinsic T cell function, and, if anything, EP2-null T cell function may be suppressed under some conditions. When bone marrow cells from wild-type or EP2-null BALB/c mice were transplanted into MHC class I congenic BALB.B mice, the resulting CD8 CTL from either background did not have substantially different cytolytic activity against the recipient MHC (data not shown), further indicating that the observed effects are unlikely to be due to an alteration in T cell-intrinsic function.
PGE 2 suppresses DC differentiation by the EP2 receptor. We next assessed the role of the EP2 receptor in DCs. EP2 receptor mRNA is expressed in wild-type bone marrow progenitor cells but not in progenitors derived from EP2 -/-mice (Figure 4a ). PGE 2 has been shown to increase IL-10 production and decrease class II expression on DCs, although the PG receptor mediating these effects was not identified (16, 17) . We therefore sought to determine whether PGE 2 might act directly on DC differentiation and function through EP2-evoked responses in this system. DCs were cultured from bone marrow progenitors in medium containing varying concentrations of PGE 2 . On day 9 or 10, DCs were analyzed by FACS for the presence of CD11c, a well-defined DC differentiation marker. While we observed a PGE 2 -mediated dosedependent decrease in the number of cells expressing CD11c, no inhibition was observed in EP2 -/-animals at concentrations up to 1,000 nM (Figure 4b) . We observed
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The In the wild-type control mice, the number of cells expressing each of these markers was significantly decreased (P < 0.05) at day 9 in the presence of 100 nM PGE 2 , while there was no effect on DCs derived from EP2 -/-mice ( Figure 4 ). The concentration of PGE 2 we used in these studies is similar to the in vitro threshold concentration reported in other studies (27) and to concentrations observed in tumors in Table 2 . Incubation of DCs with the EP2 subtype selective agonist butaprost yielded essentially similar results (data not shown).
PGE 2 inhibits DC function through the EP2 receptor.
We further investigated the ability of PGE 2 -treated DCs to stimulate T cell proliferation using allogeneic MLR assays. BALB/c-derived DCs (day 9) were cultured in presence of varying concentrations of PGE 2 and mixed withC57BL/6 wild-type T cells in the absence of PGE 2 . EP2 -/-DCs exhibited increased T cell stimulation after culture with 1-50 nM PGE 2, while DCs from wild-type mice showed decreased stimulation ( Figure 5) . At concentrations of 100 nM PGE 2 , T cell proliferation stimulated by wildtype DCs was significantly decreased (P = 0.03), whereas T cell proliferation induced by DCs from EP2 -/-mice was unaffected. Thus, EP2 receptor is critical for PGE 2 -induced suppression of DC-mediated T cell activation. At doses of 1 µM PGE 2 , suppression MLR was observed in both wild-type (P < 0.003) and EP2-null mice (P < 0.01); however, these effects were observed only at concentrations greater than 100-fold over the K d for the EP2 receptor where there is significant cross-talk with other eicosanoid receptors (8) .
The EP2 receptor plays an important role in DC function in vivo. An essential function of DC is to take up antigen at the tumor site and transport it to regional lymph nodes, where it is presented to T cells. We assessed the number of DCs and T cells in tumor-draining lymph nodes from EP2 -/-and wild-type animals. We used the immunogenic BALB/c-derived MC26 (H2K d ) tumor OVA MLR T cell proliferation in wild-type and EP2-null cells. DCs were pulsed with the indicated quantity of OVA 323-339 and used to stimulate T cells bearing the OVA-specific TCR (DO11.10). Proliferation of T cells was measured by 3 [H] thymidine uptake. Wildtype T cells are represented by filled symbols, EP2 heterozygotes by shaded symbols, and EP2-null T cells by open symbols. The data are the mean ± SEM of triplicate measurements. *EP2-null value was significantly different from wild-type value (P < 0.01). **EP2-null value is significantly different from wild-type value (P < 0.001). Untreated wild-type cells (black bars), wild-type treated with 100 nM PGE 2 (gray bars), untreated EP2 -/-cells (white bars), EP2 -/-cells treated with 100 nM PGE 2 (dark gray bars). The PGE 2 dose response for CD11c expression is a representative experiment from two independent experiments with similar results. All others are from three to four independent experiments. For each graph there is a statistically significant difference between wild-type/no PGE 2 and wild-type/PGE 2 (P < 0.05); there are no statistically significant differences between EP2 -/-/no PGE 2 and EP2 -/-/PGE 2 (P > 0.05).
model, which has been proposed to express a novel, as yet unidentified, tumor-associated antigen (28, 29) . These cells express MHC class I (30) and COX-2 (R. Dubois, personal communication). Consistent with improved survival and DC function in the knockout animals, we found that there were significantly more DCs, CD4 + , and CD8 + T cells from draining lymph nodes of tumor-bearing EP2 -/-mice than tumor-bearing wild-type mice, consistent with improved DC function in EP2 -/-animals ( Figure 6 ). This increase in cell number, however, was observed only in tumor-bearing animals, with no differences in DC or T cell numbers observed between genotypes in normal lymph nodes. Importantly, the number of DCs was significantly suppressed in the draining lymph nodes of wild-type tumor-bearing animals as compared with non-tumorbearing animals, in contrast to the higher DC numbers observed in the EP2-null tumor-bearing animals as compared with EP2-null controls. These data are consistent with a tumor immunosuppressive effect in wildtype but not EP2-null animals. Supporting the notion that the immune response differences were tumor induced, no differences were observed in the fraction of activated CD4 + , CD8 + , NK T cells or NK cells in normal lymph nodes using CD69 as a marker of early activation (data not shown).
There was no significant difference in PGE 2 concentration from tumors, draining lymph nodes, or serum between tumor-bearing EP2 -/-and wild-type mice (P > 0.05; see Table 2 ). The improvement noted in DC function in EP2 -/-mice is thus unlikely to be mediated through indirect regulation of PGE 2 production and its action on other receptors.
To establish the functional significance of increased DC and CD8 + T cell numbers, the specificity of tumorspecific CTLs in a syngeneic tumor model was determined. EP2 -/-and wild-type mice were immunized with irradiated MC26 cells. Spleen cells from MC26-immunized EP2 -/-mice exhibited specific cytotoxicity for MC26 tumor cells, whereas spleen cells from MC26-immunized wild-type mice showed no detectable CTL activity (Figure 7 ). The R8 cell line, which expresses both H2 b and H2 d MHC class I molecules, used as a control for target cell specificity, was not lysed by MC26-specific CTLs (data not shown). Furthermore, RMA-S cells, which do not express MHC class I molecules and which form targets for NK cells, were also not lysed by MC26-specific CTLs (data not shown), demonstrating that the effector function of MC26-immunized spleen cells is not due to NK cell activity. Thus the MC26-specific immune reaction observed is CTL mediated, which is MHC restricted and tumor antigen specific.
Discussion
The overproduction of COX-2 and its major metabolite PGE 2 have been found in many human cancers, including colorectal tumors, lung cancer (31-34), and cancer cell lines (5, 35, 36) . Tumor-infiltrating macrophages also produce high levels of PGE 2 (37) . Our data demonstrate that the PG receptor EP2 plays a key role in PGE 2 -induced inhibition of DC differentiation and function and cancer-associated immunodeficiency. Two major host-response mechanisms known to be affected by PGE 2 are tumor angiogenesis and immune responses. We found no differences in either microvessel counts or tumor tissue VEGF levels between tumor samples of EP2 -/-and wild-type mice, rendering it unlikely that significant differences in angiogenesis underlie the observed differences in tumor growth. Multiple assays for T cell function demonstrated no significant differences between wildtype and EP2-null mice. In contrast, we observed that
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The Figure 6 ). Perhaps most significantly, tumor-specific CTLs were observed only in immunized EP2 -/-animals and not in controls. Together, these data indicate that PGE 2 acts through the EP2 receptor to inhibit the host immune response to tumors. The COX-derived metabolites have pleiotropic effects on tumor growth. Reduced tumor growth has been noted in COX-2 -/-animals (2, 38), suggesting a tumorpromoting effect of COX-2 products. However, mice with pulmonary overexpression of prostacyclin synthase exhibited significantly reduced lung tumor incidence (39) . Manipulation of PG metabolism downstream from COX produces more profound cancer reduction than COX inhibition alone and could be the basis for new approaches to understanding the pathogenesis and prevention of cancer. Our observation that tumor growth is reduced by 50% in EP2 -/-mice is particularly significant in light of the fact that the EP receptor family contains four receptors, designated EP1, EP2, EP3, and EP4, encoded by distinct genes. While the EP2 receptor plays a major role in the host response to tumors, other receptors, e.g., EP4, may also play a role through mechanisms that are distinct from the one described here.
In addition to the specific link between EP2 and antitumor immunity revealed by our study, COX products can play a role in pathological angiogenesis. It has been reported that vascular density is decreased in tumors from a wild-type background transplanted into COX-2 -/-mice (2), and EP2-mediated signals are involved in tumor angiogenesis in tumors developing in the Apc ∆716 mouse model (19) . Mechanisms underlying the differences observed in the Apc ∆716 model and the transplantable tumors used in the current studies are not clear, but may be the result of specific profiles of proangiogenic factors or tumor antigenicity in a particular tumor model.
In vitro evidence for a role for the EP2 receptor in antigen presentation has been reported by Nataraj et al. (13) , who found a decrease in the ability of PGE 2 to inhibit EP2 -/-macrophage in stimulating an allogeneic MLR. We have confirmed and extended this MLR finding with purified DCs. Moreover, we observed that the differentiation of DCs grown from wild-type bone marrow progenitors is significantly inhibited when cultured in vitro in the presence of PGE 2 , in contrast to progenitors from EP2 -/-mice, demonstrating effects of PGE 2 on progenitors of that lineage. Previous studies have shown that elevated PGE 2 promotes type 2 cytokine production in human T helper cells by impair-
Figure 6
Increased DC numbers draining lymph nodes of EP2-null mice. The number of (a) DCs, (b) CD4 + , and (c) CD8 + T cells obtained from draining lymph nodes of normal or tumor-bearing EP2 -/-mice (white bars) is increased compared with wild-type control mice (black bars). For tumor-bearing mice, single-cell suspensions from inguinal lymph nodes from tumor-bearing EP2 -/-and wild-type mice were prepared 21 days after MC26 inoculation, at which time we observed the maximum tumor-growth difference. Cells were labeled with PE-conjugated anti-I-A d , CD11c Ab's, anti-CD4, and anti-CD8 Ab's. Cells were then washed and analyzed using a FACScan flow cytometer. The total number of positive cells per mouse is shown. Each data point is from three mice.
Figure 7
CTL function is elevated in EP2 -/-mice. Spleen cells from MC26-immunized EP2 -/-(white bars) and wild-type mice (black bars) were cocultured with irradiated MC26 cells for 4 days. The cells were then washed and incubated with different ratios of 51 Cr-labeled MC26 cells. After a 6-h incubation, supernatants were harvested and radioactivity was measured using a gamma counter. The maximum and spontaneous release and the percentage of specific 51 Cr release were determined. Data shown are representative of two independent experiments with similar results.
ing IL-12 response of DCs (40, 41) . Other factors secreted by tumors dramatically affect DC maturation from precursors, including VEGF (42) . The mechanism of the PGE 2 effect on DCs may thus involve alterations in local or systemic cytokine production.
Most importantly, consistent with a role for the EP2 receptor in DC trafficking and differentiation, as well as function, we observed increased numbers of DCs and CD4 + and CD8 + T cells in tumor-draining lymphoid organs. Moreover, specific antitumor immunity in EP2 -/-mice was increased dramatically compared with controls. It is well known that DC function is critical for T lymphocyte-mediated immune responses to tumors, both in animal models and humans. Previous studies suggested that defective antigen presentation by DCs appears to be a major determinant for CTLs' nonresponsiveness to peptide antigens in tumor-bearing mice. Addition of control peptide-pulsed DCs restored specific tumor lysis (43) . Inadequate presentation of tumor antigens by host professional APCs, including DCs, is thus a major mechanism for the escape of tumors from the host immune system (42) . Cross priming of tumor antigens by host APCs, especially DCs, the most potent APCs, through the MHC class I and class II pathway has been postulated to be a necessary and efficient mechanism to induce protective CTL responses (44) (45) (46) (47) (48) (49) . Furthermore, specific inhibition of COX-2 or PGE 2 activity with specific mAb restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis (6). PGE 2 is also reported to downregulate IFN-γ production and might, in principle, thereby interfere with cell-mediated immunity (50, 51 ). Here we demonstrate that absence of the PGE 2 EP2 receptor prevents the inhibition of DC function and allows induction of specific immunity against the tumor. Thus PGE 2 secreted by tumor cells is likely responsible for this escape by signaling through the EP2 receptor on immune cells.
In conclusion, the EP2 receptor plays an important role in inhibiting the host reaction to tumor growth through diminished immune responses caused by defective DC differentiation and function. These data suggest that the development of selective antagonists against the EP2 receptor has the potential to improve host antitumor immunity. EP2-receptor antagonists may be more specific than the use of COX-2 inhibitors and avoid inhibition of products such as prostacyclin that may be beneficial in the antitumor response.
